2017 | 03 | 27

Vironova has filed a US provisional patent for analyzing viral vector content using cryoTEM

Vironova has now filed a patent for quantitative analysis of viral vector content using cryoTEM, a method that has already triggered plenty of interest amongst our customers.

In the pharmaceutical industry, viruses and virus-like particles are extensively used as carriers for gene delivery, so called viral vectors. Assessment of carrier particle content is of prime importance as it is directly linked to the efficacy of the treatment.

Negative stain TEM (nsTEM) is a standard approach for assessing this. Due to variations in staining and preparation the results are unreliable, whereas analysis using cryoTEM yields very consistent and reliable results. Vironova has now filed the patent for the quantitative analysis of viral vector content using cryoTEM.

News and events

Read about the latest news and events at Vironova.

  • All news
  • Inside Vironova
  • Open positions
  • Events and publications
VIEW MORE
VIEW MORE
VIEW MORE
VIEW MORE

On demand webinar

  • Title: Unmatched Viral Particle Analysis in Vaccine and Gene Therapy Development
  • Speaker: Josefina Nilsson, head of EM services & Martin Ryner, Strategic development manager
  • Watch webinar

Upcoming events 2017

Cell & Gene Therapy Europe 2017
6-7 December, Amsterdam
Booth 24

Vironova on MyNewsDesk

Follow us on MyNewsDesk and get the latest info on investor relations, events and company news.
Click here to get to our MyNewsDesk-page.

Press contact
For press enquiries, please contact
info@vironova.com

IR contact
Mohammed Homman
ceo@vironova.com